Brian Boulmay, MD | LCMC Health

Dr. Brian C. Boulmay

Claim this profile

University Medical Center New Orleans

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
19 reported clinical trials
31 drugs studied

Area of expertise

1

Lung Cancer

Brian C. Boulmay has run 9 trials for Lung Cancer. Some of their research focus areas include:

Stage II
Stage IV
Stage I
2

Non-Small Cell Lung Cancer

Brian C. Boulmay has run 7 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage II

Affiliated Hospitals

Image of trial facility.

University Medical Center New Orleans

Image of trial facility.

Louisiana State University Health Science Center

Clinical Trials Brian C. Boulmay is currently running

Image of trial facility.

Radiation Therapy + Cisplatin

for Head and Neck Cancer

This trial is studying if using a specific type of energy treatment alone or with a drug is better for treating patients with advanced head and neck cancer after surgery. The energy treatment kills cancer cells, and the drug helps by stopping their growth or killing them. The drug has been used for many years in the treatment of advanced cancers, including head and neck cancers, and is known for its ability to enhance the effects of the energy treatment.

Recruiting

1 award

Phase 2

19 criteria

Image of trial facility.

Chemotherapy + Radiation Therapy

for Head and Neck Cancer

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab.

Recruiting

1 award

Phase 2 & 3

21 criteria

More about Brian C. Boulmay

Clinical Trial Related

6 years of experience running clinical trials · Led 19 trials as a Principal Investigator · 7 Active Clinical Trials

Treatments Brian C. Boulmay has experience with

  • Cisplatin
  • Carboplatin
  • Pembrolizumab
  • Pemetrexed
  • Intensity-Modulated Radiation Therapy
  • Atezolizumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Brian C. Boulmay specialize in?

Is Brian C. Boulmay currently recruiting for clinical trials?

Are there any treatments that Brian C. Boulmay has studied deeply?

What is the best way to schedule an appointment with Brian C. Boulmay?

What is the office address of Brian C. Boulmay?

Is there any support for travel costs?